The development of natural and synthetic MTA1 inhibitors with improved pharmacokinetic profiles will secure the utilization of these new and targeted drugs not only for interception during early-stage prostate cancer, but also in the treatment of more advanced stages and metastatic disease. This evidence concerns the gene MTA1 and prostate carcinoma.